Article
Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.
Molecular oncology - 1 May 2026
Ojala Veera K, Ahonen Sini, Peltola Sara, Tuohisto-Kokko Aura, Esparta Olaya, Suominen Peppi, Jokilammi Anne, Farahani Iman, Chakroborty Deepankar, Dibus Nikol, Boettcher Steffen, Airenne Tomi T, Johnson Mark S, Eli Lisa D, Elenius Klaus, Kurppa Kari J
Abstract excerpt
Receptor tyrosine kinase ERBB4 (HER4) is frequently mutated in human cancer, and ERBB4 mutations have been identified in patients relapsing on targeted therapy. Here, we addressed the functional consequences of recurrent cancer-associated ERBB4 mutations that are located at regions important for receptor activation and/or are paralogous to known oncogenic hotspot mutations in other ERBB genes. Eleven out of 18...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.